THERAPEUTIC INTERCHANGE! The battlelines have been reconnoitered and the major protagonists and antagonists are headed for the front. The old nemesis "substitution" has been dressed up as "interchange:' hey are in fact equivalent terms in this therapeutic field of battle. As health professionals we are so used to making war on cancer, battling AIDS, holding the line ?~arthritis, ,and bombarding malaria-infested jungles, It IS no surpnse that we struggle tenaciously for a limited health care turf and love to do a little interprofessional skull-bashing on Saturday nights.
Therapeutic interchange is a far more explosive issue than generic interchange, which still causes propagandã arfare after almost 20 years of enabling state legislanon encouraged by the American Pharmaceutical Association (APhA). Generic interchange occurs only after patent expiration. Therapeutic interchange can result in the substitution of another chemical entity, on or off patent, for a substance still under patent protection, even a new drug just reaching the market after costly research and development. Expensive sales forces, clever and extensive marketing strategies, and decades of company image-building can be thwarted overnight, the pharmaceutical industry fears, if therapeutic substitution is carried to its possible conclusion.
The debate has suddenly escalated an order of magnitude due to a position taken by the American Association of Colleges of Pharmacy (AACP), a respected organization representing academic pharmacy, many of who~e memb~r~are generally pro-industry and supportive of positrons taken by the Pharmaceutical Manufacturers Association (PMA). The following is from the AA CP News:
At its March meeting, the AACP Board of Directors moved to reaffirm the clinical nature of pharmacy education by endorsing "the concept of therapeutic interchange of various drug products by pharmacists under arrangements in which pharmacists and authorized prescribers interrelate on behalf of the care of patients:'
The statement was developed by the American Society of Hospital Pharmacists (ASHP) and has been adopted as policy by ASHP, American Pharmaceutical Association, American Society of Consultant Pharmacists, American College of Apothecaries and National Association of Chain Drug Stores. Other national pharmacy organizations also are considering acceptance of the policy statement.
The actions of the national pharmacy groups underscore the unanimity with which all the profession's components are facing the issue of the pharmacist's role in the process of drug product selection, I The American Medical Association (AMA) did not tarry long. In an April 4 memorandum to executives of national and state pharmaceutical organizations and state boards of pharmacy, the AMA expressed concern over the AACP position, said that formulary arrangements predetermined for groups of patients are unacceptable to the AMA, and stated that it is reconsidering its longtime support of hospital formularies due to excessive concern over cost rather than patient care. The memorandum stated further that the AMA is investigating the legalities of therapeutic interchange in the outpatient setting since it provides lessphysician authority over drug selection with no reduction in responsibility for the progress of their patients. ' A further factor fueling interest in the therapeutic interchange debate is legislation approved by the U.S. Congress to include an ambulatory drug benefit for recipients of the federally funded Medicare program. This is another opportunity for the usual industry critics to begin their hue and cry of financial rape and need for curbs. Many community pharmacists are ambivalent about extended Medicare drug coverage due to red tape headaches and poor funding of existing programs for the poor (Medicaid). Some maintain that the eager endorsement of generic substitution legislation by the APhA and its affiliated state associates may have been a pyrrhic victory after all.
The AMA memorandum is particularly troubling. The American Hospital Association (AHA) endorsed the ASHP-inspired documents outlining the operation of the pharmacy and therapeutics (P&T) committee in 1959 3 and the formulary system in 1964. 4 These docu-
Drug Intelligence and Clinical Pharmacy ments have been fundamental to those pursuing therapeutic sanity and the creation of an official role for pharmacists in hospital drug therapeutics. Unfortunately, the formulary process is undisciplined or simply directed at cost containment in many hospitals. A good formulary process requires hard work by the pharmacist: effective communications with the medical staff, strong management of the P&Tcommittee process, and reasoned therapeutic analysis and leadership. These are no small tasks and many hospital pharmacists have not met the challenge. This is supported by the findings that many formularies are ineffective."
The hospital formulary concept has been extended into other managed care environments, i.e., health maintenance organizations (HMO), Veterans Administration clinics, and mental health clinics. Doering et al. reported that 30 percent of 192 reporting HMO practice some therapeutic interchange without notifying the prescriber at the time of interchange. Many states have instituted formulary committees to guide the selection of drugs for Medicaid recipients. The bigger the organization the greater the fear of some that stifling bureaucracy and lack of concern for individual physicians and patients will fundamentally alter the current balance of influence in therapeutics.
One great difficulty in this debate is a working definition of therapeutic interchange. Generic interchange is much simpler: the active chemical entity, strength, dosage form, and bioavailability should be equivalent. The major argument relates to the methodology and frequency of bioavailability assessment. What does therapeutic equivalency mean and which data will the pharmacist need to make an informed decision?
A few examples will illustrate the potential complexity of the issue. The various tetracyclines are generally considered to be equivalent and to possess similar adverse effects, so why not substitute the cheapest one for any prescription in the tetracycline class? There are, in fact, differences in the effects of the agents. For example, doxycycline is the preferred agent in renally impaired patients since its clearance and serum half-life are not altered and it does not increase blood urea nitrogen as do the other agents. Only demeclocycline has an unusual effect of opposing the syndrome of inappropriate antidiuretic hormone and can be used to treat the condition. Minocycline may be used in cases of acne resistant to tetracycline and erythromycin. Without medical information and physician consultation, there is potential harm in what could appear to be simple therapeutic substitution.
Anticonvulsants, antineoplastics, antibiotics for treatment of unusual or resistant microorganisms, and antiarrhythmics represent other classes of drugs where therapeutic substitution without the full knowledge and consent of the physician would be foolhardy. Some drugs are chosen only after careful trial and error by the physician, e.g., antiarthritics, antihypertensives, insulin, antiparkinson agents, and antipsychotics. Topical corticosteroid potency is influenced by the vehicle and formulation techniques, and thus generic equivalents may not be therapeutic equivalents.
In asthmatic therapy, it could be construed that under some circumstances therapeutic interchange could occur among regular and extended-release theophylline, beta-adrenergic bronchodilators, cromolyn, or beclomethasone inhalation. Ridiculous example, one may say, but therapeutic interchange is not well defined. Some pharmacists are claiming they are "the" drug experts. Where does it start and end?
The state of Washington has passed the most reasonable legislation to date.?:" Concerned that narrowly interpreted pharmacy and medical regulations could be used to reverse some progressive therapeutic practices developing in hospitals and HMO, the pharmacy act was amended in two ways: (1) to allow therapeutic interchange of drugs under conditions of a prior written consent agreement with a physician and (2) to recognize prescriptive authority as an aspect of pharmacy practice when there exists a written prescriptive protocol agreement between a physician and pharmacist for the care of that physician's patients. This legislation was enacted to protect already developed practices. For example, using principles of pharmacokinetics and therapeutic monitoring some clinical pharmacists have proven highly adept at dosing aminoglycosides in the hospital environment. The physician may simply prescribe "gentamicin per pharmacy consult!' A narrowly interpreted state pharmacy act might not allow the practice since a properly written prescription must contain the dose, route of administration, etc. These legislative changes have benefited patients in hospitals and HMO, but probably have had no measurable impact on community pharmacy practice in Washington.
Similar legislation was attempted later in Oregon, but with the opposition of industry lobbyists, the legislation was defeated." Oregon pharmacists thus may experience legal recourse when they practice in a progressive manner similar to their Washington neighbors.
Wisconsin has passed legislation restricting therapeutic interchange to hospitals that use a prescribed formulary, have concurrence of the P&T committee, and obtain final approval of the prescribing physician. 10 Lobbying efforts there were successful in eliminating HMO from coverage, although pharmacy-medicine protocols in theory should be permissable.
The Wall Street Journal has brought the issue, albeit cloudily, before the public. II A survey in American Druggist reports that 80 percent of community pharmacists (chain and independent) and 87 percent of hospital pharmacists feel qualified to undertake therapeutic substitution (definition or examples not given). Half of the pharmacists polled said that therapeutic interchange should be allowed in retail settings with the physician's consent, and 22 percent said it should be allowed in any setting with or without consent. 11 With the physician dispensing debate simultaneously heated in the U.S., the likelihood of interprofessional acrimony appears great. The PMA and AMA will close rank and seek support of every national specialty medical society and disease-oriented voluntary organization in an attack on therapeutic interchange. The PMA strategy for this and other lobbying efforts is already documented. 13.14 In my opinion, legislative approaches and organizational power plays by pharmacy, medicine, or the drug industry will create patient care problems. Those phar-
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macists who deserve to practice therapeutic interchange are those who have gained the active consent of the prescriber. In a well-operated hospital, with a P&T committee and a well-defined formulary, a non formulary order is not simply substituted with a different chemical entity. The physician is contacted, his consent for change is sought, and proper notation is made in the medical record so that nurses and others can carry out orders correctly. The personal contact with the physician is important; its educational and image-building value will result in a high degree of future compliance with a rational drug formulary. When therapeutic substitution is attempted unilaterally, the patient is not receiving the optimal benefits of the professions' coordinated care. Some cases of therapeutic substitution are straightforward, but where does it start and end? There are no defined ground rules. There are currently economic pressures causing the natural development of thoughtful therapeutic protocols and prior written consent agreements at managed health care sites and facilities. These concepts can also be practiced by individual pharmacists and physicians in independent practices regardless of lobbying efforts to the contrary. One positive aspect of the Washington legislation is provision requiring notification of the board of pharmacy of such agreements so that developments can be monitored for reasonableness. Health care administrators must be sensitive to the quality of therapeutics and not coerce physicians into unsafe therapeutic arrangements or those not based on high-quality care. The practices of medicine and pharmacy will be more enjoyable with mutual comraderie and respect. This is attainable in most hospitals and HMO environments if good professionals are employed. Pharmacy needs to concentrate on performance, not rhetoric.
In a show of unity, the Washington State Medical Association, the Washington State Pharmacists Association, and the Washington State Society of Hospital Pharmacists issued a joint letter to their members explaining the merits of the Washington legislation and asking for local communications and understanding. IS These methods are to be preferred over battles among medicine, pharmacy, and the pharmaceutical industry in a quest for prescriptive prerogative.
